AIM: To investigate the effect of polysomy 17 on HER-2 status as evaluated by immunohistochemistry (IHC), dual-colour fluorescence in situ hybridisation (FISH) and chromogenic in situ hybridisation (CISH). METHODS: Dual-probe FISH and single-probe CISH were performed to detect HER-2 gene amplification, and IHC to detect HER-2 expression, on 309 invasive breast cancers. RESULTS: Polysomy 17 was detected in 32.0% of the total number of breast cancers; it was detected in 12.3% of the IHC 0 or 1+ cases, 42.8% of the IHC 2+ cases and 66.0% of the IHC 3+ cases (p<0.001). In addition, there was a substantially higher rate of polysomy 17 in the IHC 2+ or 3+/FISH-negative cases than in the IHC 0 or 1+ cases (40.8% vs 12.3%; p<0.001). The FISH and CI...
Background: Amplification/overexpression of c-erbB-2/Her-2 can predict the prognosis and the efficie...
HER2 gene amplification in invasive breast cancer is a robust predictive marker for response to tran...
HER2 gene amplification in invasive breast cancer is a robust predictive marker for response to tran...
AIM: To investigate the effect of polysomy 17 on HER-2 status as evaluated by immunohistochemistry (...
PURPOSE: Polysomy 17 is frequently found in breast cancer and may complicate the interpretation of H...
Aims: HER2 testing of invasive breast cancer by in-situ hybridization guides therapy decisions. Prob...
Aims: HER2 testing of invasive breast cancer by in-situ hybridization guides therapy decisions. Prob...
Monosomy of chromosome 17 may affect the assessment of HER2 amplification. Notably, the prevalence r...
AbstractIt has been proven that chromosome 17 centromere (CEP17) amplification causes misleading hum...
Aberrations of chromosome 17 are common in breast cancer. Fluorescence in situ hybridization (FISH) ...
The prevalence of HER2 amplification according to the percentage of positively stained cells, of pol...
Introduction: One of the most common genetic aberrations associated with breast cancer is the amplif...
Introduction: One of the most common genetic aberrations associated with breast cancer is the amplif...
Trastuzumab-containing therapy is a standard of care for patients with HER2+ breast cancer. HER2 sta...
Background: In diagnostic pathology, HER2 status is determined in interphase nuclei by fluorescence ...
Background: Amplification/overexpression of c-erbB-2/Her-2 can predict the prognosis and the efficie...
HER2 gene amplification in invasive breast cancer is a robust predictive marker for response to tran...
HER2 gene amplification in invasive breast cancer is a robust predictive marker for response to tran...
AIM: To investigate the effect of polysomy 17 on HER-2 status as evaluated by immunohistochemistry (...
PURPOSE: Polysomy 17 is frequently found in breast cancer and may complicate the interpretation of H...
Aims: HER2 testing of invasive breast cancer by in-situ hybridization guides therapy decisions. Prob...
Aims: HER2 testing of invasive breast cancer by in-situ hybridization guides therapy decisions. Prob...
Monosomy of chromosome 17 may affect the assessment of HER2 amplification. Notably, the prevalence r...
AbstractIt has been proven that chromosome 17 centromere (CEP17) amplification causes misleading hum...
Aberrations of chromosome 17 are common in breast cancer. Fluorescence in situ hybridization (FISH) ...
The prevalence of HER2 amplification according to the percentage of positively stained cells, of pol...
Introduction: One of the most common genetic aberrations associated with breast cancer is the amplif...
Introduction: One of the most common genetic aberrations associated with breast cancer is the amplif...
Trastuzumab-containing therapy is a standard of care for patients with HER2+ breast cancer. HER2 sta...
Background: In diagnostic pathology, HER2 status is determined in interphase nuclei by fluorescence ...
Background: Amplification/overexpression of c-erbB-2/Her-2 can predict the prognosis and the efficie...
HER2 gene amplification in invasive breast cancer is a robust predictive marker for response to tran...
HER2 gene amplification in invasive breast cancer is a robust predictive marker for response to tran...